

Regeneus Ltd

09:20 29 Dec 2016

Regeneus teams up with world-leading manufacturer in Japan

Regeneus (ASX:RGS) has entered into a strategic collaboration and licensing agreement for the manufacture, clinical development and commercialisation of Progenza in the Japanese market.

Progenza is a patented off-the-shelf stem cell technology developed for the treatment of knee osteoarthritis and other inflammatory conditions.

Regeneus has entered the agreement with Asahi Glass Co (TYO:5201), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals.

Under the agreement, Regeneus will receive US\$16.5 million from Asahi Glass in exchange for exclusive manufacturing rights in Japan and a 50% interest in Regeneus Japan.

Asahi Glass will be responsible for funding the manufacture of Progenza for the proposed Phase 2 trial for osteoarthritis in Japan under specific conditions.

The market in Japan for regenerative medicines is projected to grow to US\$12.7 billion by 2030 according to the Japanese government.

John Martin, CEO, commented:

"As a leading manufacturer of biopharmaceutical products in Japan with recent acquisitions of manufacturing capability in Europe and the U.S, Asahi Glass is well placed to expand into the fast growing market for manufacturing regenerative medicine products."

Terms of agreement

As per the agreement, Regeneus is to receive US\$16.5 million comprised of \$5.5 million upfront and US\$11 million in specified milestone payments.

This will see Regeneus and Asahi Glass establish a 50/50 joint venture for exclusive clinical development and commercialisation of Progenza for osteoarthritis and all inflammatory conditions for the Japanese market.

Regeneus will also be entitled, through its 50% interest in the joint venture, to its share of upfront licence fees, milestone payments and royalties from any sub licensing.

Background

Regeneus is an emerging leader in cell based medicines for both humans and animals.

Price: A\$0.145

Market Cap: A\$30.288M

1 Year Share Price Graph



Share Information

Code: RGS

Listing: ASX

52 week High Low
0.185p 0.071p

Sector: Health Care, Equipment & Services

Website: www.regeneus.com.au

Company Synopsis:

Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies with a focus on musculoskeletal disease, oncology and dermatology.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

It is a clinical-stage regenerative medicine company with a focus on osteoarthritis and other musculoskeletal disorders, oncology (cancer) and dermatology diseases.

Over the last 12 months, Progenza has been evaluated as a treatment for knee osteoarthritis in a Phase 1 trial conducted in Sydney.

A safety review of both treatment cohorts found there were no safety or tolerability concerns with Progenza.

All patients are being followed for 12 months and the study results will be made available in the second quarter of 2017.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.